P2.07-037 Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab
JOURNAL OF THORACIC ONCOLOGY(2017)
摘要
Despite significant improvement of clinical outcomes of the patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors, our knowledge of optimal predictive and prognostic biomarkers are still evolving.
更多查看译文
关键词
biomarker,Advanced Non-Small Cell Lung Cancer,Nivolumab
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要